Literature DB >> 8201603

Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin.

M F Stevens1, C J McCall, P Lelieveld, P Alexander, A Richter, D E Davies.   

Abstract

A series of polyhydroxylated 2-phenylbenzothiazoles 3 has been prepared by demethylation of the precursor methoxylated 2-phenylbenzothiazoles 9. The key step in the construction of the benzothiazole nucleus involves a Jacobson cyclization of methoxylated thiobenzanilides 8. The target compounds inhibit WiDr human colon tumor cells and MCF-7 human mammary tumor cells in vitro with IC50 values in the low micromolar range, but the activity against MCF-7 cells is not related to estrogen receptor-binding affinity. None of the compounds showed selective cytotoxicity against Abelson virus-transformed ANN-1 cells encoded with the pp120gag-abl tyrosine kinase compared with the parental 3T3 line. Compounds were only marginally inhibitory to the EGF receptor-associated protein tyrosine kinase from a membrane preparation of A431 cells. The most active compound was 4,6-dihydroxy-2-(4-hydroxyphenyl)benzothiazole (3b) which has the same overall hydroxyl substitution pattern as genistein (1a). The compounds were weakly cytotoxic for an EGF receptor, overexpressing cell line HN5, but when tested for differential toxicity against the EGF receptor tyrosine kinase or the PDGF receptor tyrosine kinase in a standard mitogenesis assay utilizing human fibroblasts, no discrimination was observed. In this assay, the compounds inhibited DNA synthesis when added to cells during S phase. This suggests that inhibition could not be interpreted in terms of tyrosine kinase inactivation but more likely as a relatively broad specificity for the ATP-binding domain of other kinases such as thymidine kinase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8201603     DOI: 10.1021/jm00037a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals.

Authors:  J Zheng; V D Ramirez
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

2.  Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers.

Authors:  Ibrahim H Eissa; Radwan El-Haggar; Mohammed A Dahab; Marwa F Ahmed; Hazem A Mahdy; Reem I Alsantali; Alaa Elwan; Nicolas Masurier; Samar S Fatahala
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Halothane, a novel solvent for the preparation of liposomes containing 2-4'-amino-3'-methylphenyl benzothiazole (AMPB), an anticancer drug: a technical note.

Authors:  Yingqing Ran; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

4.  Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35).

Authors:  I N Singh; G Sorrentino; J N Kanfer
Journal:  Neurochem Res       Date:  1998-10       Impact factor: 3.996

5.  2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.

Authors:  T D Bradshaw; S Wrigley; D F Shi; R J Schultz; K D Paull; M F Stevens
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

6.  Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).

Authors:  T D Bradshaw; M S Chua; S Orr; C S Matthews; M F Stevens
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

7.  Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo.

Authors:  T D Bradshaw; D F Shi; R J Schultz; K D Paull; L Kelland; A Wilson; C Garner; H H Fiebig; S Wrigley; M F Stevens
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.